P/E ratio for Santen Pharmaceutical (4536.T)
P/E ratio as of April 2024 (TTM): -49.7
According to Santen Pharmaceutical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -49.7239. At the end of 2022 the company had a P/E ratio of -45.5.
P/E ratio history for Santen Pharmaceutical from 2009 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -45.5 | -161.87% |
| 2021 | 73.5 | 167.24% |
| 2020 | 27.5 | -4.89% |
| 2019 | 28.9 | 40.3% |
| 2018 | 20.6 | -8.54% |
| 2017 | 22.5 | -21.09% |
| 2016 | 28.6 | 95.1% |
| 2015 | 14.6 | -40.78% |
| 2014 | 24.7 | 8.84% |
| 2013 | 22.7 | 33.9% |
| 2012 | 17.0 | 32.54% |
| 2011 | 12.8 | -8.65% |
| 2010 | 14.0 | 4.41% |
| 2009 | 13.4 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.